Abacus Global(ABL.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Abacus Global
ABL.US
Abacus Global Management, Inc. operates as an alternative asset manager and market maker in the United States. It operates in five segments: Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. The Active Management segment is involved in the buying, selling, and trading of policies; and the maintenance of policies until receipt of death benefits.
322.12 B
ABL.USMarket value -Rank by Market Cap -/-

Financial Score

27/01/2026 Update
B
Insurance BrokersIndustry
Industry Ranking14/33
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.19%C
    • Profit Margin5.62%C
    • Gross Margin87.84%A
  • Growth ScoreA
    • Revenue YoY91.93%A
    • Net Profit YoY192.58%A
    • Total Assets YoY92.52%A
    • Net Assets YoY70.43%A
  • Cash ScoreA
    • Cash Flow Margin1780.13%B
    • OCF YoY91.93%A
  • Operating ScoreD
    • Turnover0.28D
  • Debt ScoreC
    • Gearing Ratio52.16%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says

    Abbott Laboratories anticipates growth in H2 2026, driven by new product launches and a recovery in its Nutrition and Diagnostics sectors, according to RBC Capital Markets. Despite facing near-term challenges, the company projects organic revenue growth of 6.5% to 7.5% and adjusted EPS of $5.55 to $5.80. RBC maintains an outperform rating but has lowered its price target to $135 from $147. MedTech and Established Pharmaceuticals showed growth, contributing to a total organic growth of 3.8%.

    fidelity·
    US
    IHE
    +0.08%
    US
    ABT
    +1.26%
    US
    XLV
    +0.39%
    fidelity·
    US
    IHE
    +0.08%
    US
    ABT
    +1.26%
    US
    XLV
    +0.39%

    Evercore ISI Sticks to Their Buy Rating for Abbott Laboratories (ABT)

    Evercore ISI analyst Vijay Kumar has reaffirmed a Buy rating for Abbott Laboratories (ABT) with a price target of $138.00. Kumar, who specializes in the Healthcare sector, has an average return of 3.4% and a 52.40% success rate on his stock recommendations. Additionally, Bernstein's Lee Hambright also issued a Buy rating for Abbott, while TipRanks – xAI maintained a Hold rating on the stock.

    Tip Ranks·
    US
    IHE
    +0.08%
    US
    XHE
    +0.26%
    US
    XLV
    +0.39%
    Tip Ranks·
    US
    IHE
    +0.08%
    US
    XHE
    +0.26%
    US
    XLV
    +0.39%

    Abbott Laboratories achieves double-digit earnings growth

    Abbott Laboratories reported double-digit earnings growth, driven by its mission to enhance health through innovative technologies and products. The company's current stock price is $120.73, with a market capitalization of $209.9 billion and an enterprise value of $215.2 billion. Its trailing P/E ratio is 15.2, while the forward P/E is 21.8, indicating moderate earnings relative to price. The PEG ratio stands at 2.26, suggesting slower expected growth compared to its valuation. Other financial metrics include P/S at ~4.8, P/B at ~4.1, and EV/EBITDA at ~18.3.

    Alpha Street·
    US
    IXJ
    +0.71%
    US
    ABL
    0.00%
    US
    IHE
    +0.08%
    Alpha Street·
    US
    IXJ
    +0.71%
    US
    ABL
    0.00%
    US
    IHE
    +0.08%

    Abbott Laboratories Q4 Adjusted Earnings, Revenue Rise; Issues Q1, Full Year 2026 Adjusted Earnings Guidance

    Abbott Laboratories Q4 Adjusted Earnings, Revenue Rise; Issues Q1, Full Year 2026 Adjusted Earnings Guidance

    marketscreener·
    US
    IHE
    +0.08%
    US
    ABT
    +1.26%
    US
    VHT
    +0.39%
    marketscreener·
    US
    IHE
    +0.08%
    US
    ABT
    +1.26%
    US
    VHT
    +0.39%

    What To Expect From Abbott Laboratories’s (ABT) Q4 Earnings

    Abbott Laboratories is set to report its Q4 earnings this Thursday, with analysts expecting a revenue growth of 7.6% year on year to $11.8 billion and adjusted earnings of $1.49 per share. The company has met revenue expectations in the past but has missed Wall Street's estimates four times in the last two years. Currently, Abbott's stock is down 2.9% over the past month, with an average analyst price target of $144.75, while the current share price is $121.24.

    Stock Story·
    US
    ARKG
    -0.46%
    US
    IHE
    +0.08%
    US
    IHI
    +0.76%
    Stock Story·
    US
    ARKG
    -0.46%
    US
    IHE
    +0.08%
    US
    IHI
    +0.76%
    © 2026 Longbridge｜Disclaimer